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Abstract: Purpose: The aim of this study was to compare the evolution of systemic cytokine levels over 
time in patients with pneumococcal pneumonia treated either with ß-lactam monotherapy or with 
combination therapy (ß-lactam plus fluoroquinolone). 
Methods: Prospective observational study of hospitalized non-immunocompromised adults with PP. 
Concentrations of IL-6, IL-8, IL-10 and TNF-α were determined on days 0, 1, 2, 3, 5, and 7. Patients on 
ß-lactam monotherapy were compared with those receiving combination therapy.  
Results: Fifty-two patients were enrolled in the study. Concentrations of IL-6, IL-8, and IL-10 decreased 
rapidly in the first days after admission, in accordance with the mean time to defervescence. High 
levels of IL-6 were found in patients with the worst outcomes, measured by the need for intensive care 
unit admission and mortality. No major differences in demographic or clinical characteristics or 
severity of disease were found between patients treated with ß-lactam monotherapy or combination 
therapy. IL-6 levels fell more rapidly in patients with combination therapy in the first 48 hours 
(p=0.016).  
Conclusions: Our data suggest that systemic expression of IL-6 production in patients with PP is 
correlated with prognosis. Initial combination antibiotic therapy produces a faster decrease in this 
cytokine in the first 48 hours.  
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Comments to the Author: 
 
Reviewer #1: Prospective, non randomized study on the evolution and the impact of antibiotic therapy 
on systemic cytokine expression in pneumococcal pneumonia. 
A total of 52 patients enrolled. Data on the evolution of the systemic cytokine levels obtained every 24 
hours during the first 5 days and on day 7. In 39 selected patients, the impact of B-lactam alone vs. B-
lactam plus fluoroquinolone on the systemic cytokine levels was assessed.  
Results showed that high levels of IL-6 at inclusion predicted the worst outcomes, including admission 
to ICU and mortality. In the group of patients treated with the combination, IL-6 levels fell more rapidly 
in the first 48 hours.  
  
COMMENTS  
The study confirms previous reports that have shown a correlation of IL-6 levels at entry and 
prognosis. The results of the comparative study on the impact of antibiotic therapy showed that 
combination therapy was associated with a faster decrease in IL-6 in the first 24 and 48 hours of 
treatment. The Introduction, Methods and Results are appropriate and pertinent information is 
provided. 
In the Discussion, the authors elaborate considerably on the potential advantages of combination vs. 
monotherapy in CAP and pneumococcal pneumonia. This is unnecessary. First, this issue is not settled 
and no randomized trials have been performed to answer this question and, second, as the authors 
themselves acknowledge, they did not intend to determine whether combination therapy had a better 
impact on survival than monotherapy. In addition, most studies have used the combination of B-lactam 
plus macrolide, not B-lactam plus fluroquinolone.  
R: According to the reviewer's comment, we have deleted the sentences discussing the potential 
advantages of combination versus monotherapy. We have added information regarding the point that 
most studies have used the combination of B-lactam plus macrolide, not B-lactam plus fluroquinolone 
(page 20, lines 21 and 22).  
 
Also, they state that the role of fluoroquinolone monotherapy as empirical treatment for severe CAP 
has not been established. This is not correct. The IDSA/ATS guidelines recommend precisely 
fluoroquinolne monotherapy as one of the options. Besides, they should not refer to CAP, they should 
be addressing the issue of pneumococcal pneumonia. 
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Purpose: The aim of this study was to compare the evolution of systemic cytokine levels 
over time in patients with pneumococal pneumonia treated either with -lactam 
monotherapy or with combination therapy (-lactam plus fluoroquinolone). 
Methods: Prospective observational study of hospitalized non-immunocompromised 
adults with PP. Concentrations of IL-6, IL-8, IL-10 and TNF- were determined on days 
0, 1, 2, 3, 5, and 7. Patients on -lactam monotherapy were compared with those 
receiving combination therapy.  
Results: Fifty-two patients were enrolled in the study. Concentrations of IL-6, IL-8, and 
IL-10 decreased rapidly in the first days after admission, in accordance with the mean 
time to defervescence. High levels of IL-6 were found in patients with the worst 
outcomes, measured by the need for intensive care unit admission and mortality. No 
major differences in demographic or clinical characteristics or severity of disease were 
found between patients treated with -lactam monotherapy or combination therapy. IL-6 
levels fell more rapidly in patients with combination therapy in the first 48 hours 
(p=0.016).  
Conclusions: Our data suggest that systemic expression of IL-6 production in patients 
with PP is correlated with prognosis. Initial combination antibiotic therapy produces a 
faster decrease in this cytokine in the first 48 hours.  




































































Streptococcus pneumoniae remains a major cause of disease worldwide [1]. Among 
pneumonia pathogens, it is the most common cause of hospitalization in adults and the 
most frequent cause of death [2,3]. Despite improvements in etiologic diagnosis, 
effective antibiotic therapy and advances in supportive care, the morbidity and mortality 
rates associated with pneumococcal pneumonia (PP) remain high. Case-fatality rates for 
bacteremic pneumococcal pneumonia range between 7 and 35% [4].  
A recent study [5] of the factors associated with early death in patients with community-
acquired pneumonia (CAP) reinforces the classical concept that some deaths are closely 
related to inadequate host response [6]. Excessive cytokine response in patients with 
severe CAP has been linked with deleterious effects and poor prognosis [7-14]. 
However, most studies included populations that were heterogeneous in terms of 
patients, etiologies, and treatment. Significantly, specific studies of the role of cytokine 
response for predicting poor outcomes in patients with PP are scarce. In recent years, 
the modulation of the inflammatory response has emerged as a promising concept for 
improving the outcomes of CAP. Although it has been suggested that different antibiotic 
classes may have different effects on the systemic expression of cytokine production [15-
17], information addressing this issue in PP is lacking.   
We carried out a prospective study in order to (i) analyze the relationship between 
systemic expression of cytokine production and outcomes in patients with PP and (ii) 
compare the evolution of systemic cytokine levels over time in patients treated either with 




































































MATERIAL AND METHODS 
Study subjects and study design. The study was carried out in a 900-bed university 
hospital for adults in Barcelona, Spain. The hospital serves an area of 1,100,000 
inhabitants and admits approximately 24,000 patients per year. All non-
immunocompromised patients with PP who were admitted to the hospital from January 
2005 through December 2005 were prospectively recruited and followed up. Patients 
with neutropenia, HIV infection or transplantation were not included. Concentrations of 
circulating cytokines were determined for all patients. To assess the effects of treatment 
on the systemic expression of cytokine production, patients were divided into two groups: 
those initially treated only with -lactams (-lactam group), and those initially treated with 
combination therapy including -lactams plus fluoroquinolone (combination therapy 
group). This prospective longitudinal observational study was approved by the Ethical 
Committee of our Institution. 
Clinical evaluation and follow-up. At the initial visit, and before starting empirical 
antibiotic therapy, patients underwent a complete clinical history, physical examination 
and laboratory testing. Microbiological studies included two sets of blood cultures and 
sputum Gram stain and culture when available. Urinary antigen detection for S. 
pneumoniae was performed if indicated by the attending physician. Antimicrobial 
susceptibility was tested by the microdilution method, following the Clinical Laboratory 
Standard Institute methods and criteria [18,19].  
Empiric antibiotic therapy was administered according to the hospital’s guidelines, which 
recommend the administration of a ß-lactam agent (ceftriaxone or amoxicillin-
clavulanate) with or without a fluoroquinolone (levofloxacin). Combination therapy was 



































































or in case of severe CAP in the absence of a demonstrative sputum Gram stain. 
Levofloxacin monotherapy was allowed for selected cases (i.e., those patients with 
allergy to ß-lactam agents and no prior quinolone use). 
Patients were seen daily during their hospital stay by one or more of the investigators 
who provided medical advice when requested and recorded demographic 
characteristics, underlying disease, clinical features, vaccination status, causative 
agents, therapy, and outcomes in a computer-assisted protocol.   
Definitions. PP was diagnosed in patients with signs and symptoms of an acute-onset 
lower respiratory tract infection, a new infiltrate on chest radiograph, and one or more 
cultures positive for S. pneumoniae obtained from blood, normally sterile fluids, or 
sputum and/or a positive test for detection of urinary antigen. Only good quality samples 
of sputum (<10 squamous epithelial cells and >25 leucocytes per field) were accepted 
for processing. S. pneumoniae was identified using standard microbiology procedures. 
S. pneumoniae antigen in urine was detected by using a rapid immunochromatographic 
assay (NowTM, Binax, Portland, ME, USA). 
Antimicrobial susceptibility was tested by microdilution. S. pneumoniae strains were 
serotyped. Molecular characterization was performed by pulsed field gel electrophoresis 
after restriction with Sma(I) and selected strains were analysed by MLST, as previously 
reported [1].  
The diagnosis of septic shock was based on a systolic blood pressure of less than 90 
mmHg and peripheral hypoperfusion with clinical suspicion of uncontrolled infection. 
Early death was defined as death due to any cause < 48 hours of hospitalization. Overall 
mortality was defined as that due to any cause within 30 days of hospitalization. The 
severity of illness at presentation was quantified using the validated PORT prediction 



































































Collection of blood samples and laboratory processing. For all patients, serial 
venous blood samples were collected at inclusion, immediately prior to the initiation of 
antibiotic therapy, and on days 1, 2, 3, 5, and 7. The blood obtained was placed in tubes 
containing EDTA, immediately centrifugated, and stored at – 80ºC. The assays were 
performed by one of the authors (M.C.), who was blinded to the clinical details of 
individual patients. The circulating levels of cytokines IL-6, IL-8, IL-10 and TNF- were 
measured.  
IL-6, IL-8, IL-10 and TNF-, concentrations were measured using commercially available 
kits (GENZYME, Cambridge, Mass). The procedure consisted of a solid-phase 
chemiluminescent immunometric assay. The standards defined in the operator’s manual 
were applied. The limits of detection were 3 pg/ml for IL-6, 1 pg/ml for IL-8, 4 pg/ml IL-10 
and 0.5pg/ml for TNF-. 
Statistical analysis. To analyze the relationship between systemic expression of 
cytokine production and the severity of PP we compared serial serum cytokine 
measurements in patients who had severity markers (bacteremia, ICU admission and 
mortality) with those who did not. A comparison of serial cytokine measurements was 
made with the Kruskal-Wallis one-way analysis of variance nonparametric test.  
To assess the effects of treatment on the systemic expression of cytokine production, we 
compared the combination therapy and –lactam groups. Patients who initially received 
other antibiotic treatments were excluded. To detect significant differences between 
groups we used the chi-square test with continuity correction for categorical variables. 
Normally distributed data were compared by using unpaired t tests and the Mann-
Whitney U-test was used for analysis of variables with non-normal distribution. Studies 
evaluating serum concentrations of cytokines over time (the fall-down pattern) were 



































































within-subject and between-subject factors (differences attributable to antimicrobial 
therapy). The contrasts selected were “difference” and “polynomic” for within subject 
factors. The analysis was adjusted for potential confounding variables (use of 
corticosteroids or ICU admission). The data analyses were performed with SPSS 
software version 13.0. In all analyses, we considered P values less than 0.05 to be 
statistically significant.  
 
RESULTS 
Characteristics of patients and evolution of cytokines over time. Fifty-two 
hospitalized patients with PP were included. Their demographic characteristics and main 
clinical features are shown in Table 1. The diagnosis of PP was established with the use 
of one or more of the following methods: blood culture (21 cases), sputum Gram stain 
and culture (20 cases), urinary antigen test (17 cases), and transthoracic needle 
aspiration (2 cases). All S. pneumoniae were susceptible to ciprofloxacin (MIC range 0.5-
2 µg/ml) and to levofloxacin (MIC range 0.5-1µg/ml). Using current non-meningeal 
breakpoints for beta-lactams, all strains were penicillin (MIC range 0.03-2 µg/ml), 
amoxicillin (MIC range 0.03-2 µg/ml) and cefotaxime (MIC range 0.03-1 µg/ml) 
susceptible. The most frequent serotypes were 3, 1 and 5, which accounted for 51.4% of 
strains. These serotypes were related to ST260 and ST180 for serotype 3, ST306 for 
serotype 1. 
Concentrations of all the cytokines studied were detected in peripheral venous blood 
samples in all patients, although with a wide range of values. Figure 1 shows the 
evolution of cytokines over time. At admission, IL-6 and IL-8 showed the highest values. 



































































TNF-, showed a statistically significant trend towards a rapid decrease after 24 to 48h. 
TNF- remained basically unmodified throughout the study period.  
Clinical outcomes and their relationship with systemic cytokines. The main 
outcomes of patients are summarized in table 2. Mean time to defervescence was 2.19 
days (SD 1.19). After the initial evaluation in the emergency department, 37 (71.2%) 
patients were admitted to a conventional hospital ward, whereas the other 15 (28.8%) 
were transferred to an intensive care unit (ICU). The median length of ICU stay was 7 
days (range 2-72 days). The early and overall case-fatality rates were 1.9% and 15.4% 
respectively. The evolution of systemic cytokines concentration over time in relation to 
bacteremia was determined, as well as ICU admission and mortality. Table 3 shows 
serum levels of cytokine on days 0, 1, and 2 in relation to these outcomes. In summary, 
no significant differences in cytokine levels were found in patients with or without 
bacteremia. IL-6 was significantly higher in patients requiring ICU admission and in 
patients who died. High levels of IL-8, especially on day 1, were also documented in 
patients with ICU admission and in those who died.   
On day 0, the third quartile for IL-6 initial concentrations identified 83.3% non-survivors 
and only 16.2% survivors. Thus, at admission, an IL-6 level > 5206 pg/ml predicted 
mortality with a sensitivity of 100%, a specificity of 79.3%, a positive predictive value of 
80.6%, and a negative predictive value of 100%. On day 1, levels of IL-6 > 4097 pg/ml 
predicted mortality with a sensitivity of 100%, a specificity of 100%, a positive predictive 
value of 80%, and a negative predictive value of 94.3%. 
Effects of antibiotic treatment on cytokine production. To assess the effects of 
treatment on systemic cytokine production, we compared 19 patients in the –lactam 
group (ceftriaxone in 15 cases and amoxicillin-clavulanate in four) with 20 patients in the 



































































(five initially treated with combination therapy [–lactam plus macrolide], four initially 
treated with linezolid and four initially treated with a single fluoroquinolone treatment 
were excluded from the analysis. There were no differences in the characteristics of the 
patients who were included and those who were excluded. Demographic characteristics, 
the main clinical features and outcomes of patients by treatment group are shown in 
Table 4. Interestingly, no important differences in demographic characteristics, 
vaccination status, time from pneumonia onset to inclusion, previous use of steroids, 
statins, non-steroidal anti-inflammatory drugs, severity of infection, bacteremia and 
outcomes were found between groups. Chronic heart and cerebrovascular diseases 
were more frequent in patients in the –lactam group. Conversely, the presence of 
multilobar infiltrates was more frequent in the combination therapy group.  
As shown in figure 2, the IL-6 decrease was more rapid in the combination therapy 
group, particularly in the first days (p=0.016). TNF- levels were lower in the combination 
therapy group, but the differences did not reach statistical significance. No differences in 
the evolution over time of IL-8 were detected. Conversely, levels of anti-inflammatory 
cytokines (IL-10) remained higher (p<0.001) in the combination therapy group. All these 




Previous studies of CAP have noted that most cytokines can be detected in systemic 
circulation and show a significant pattern of decline in the first hours of treatment. 
Indeed, all cytokines studied in the present report were detected in venous blood 
samples in patients with PP at hospital admission. Thus, most patients developed a 



































































Interestingly, all these cytokines, except for TNF-, declined in the first 48 hours. These 
decreases correlate clinically with the time to clinical defervescence.   
Previous studies have reported that an excess of proinflammatory cytokines is 
associated with poor prognosis of CAP [7-14]. Our results showed a similar relationship 
between high levels of cytokines and poor outcomes in the specific population with PP. 
We demonstrated that levels of IL-6 on admission, as well as levels of Il-6 and IL-8 in the 
first 48h, were the best markers for predicting poor outcomes, in agreement with 
previous studies analyzing any etiology of CAP. A recent study11 found that the addition 
of biological markers such as C-reactive protein to severity scoring systems (PSI, CURB-
65 and CRB-65) improves the 30-day mortality prediction. Further studies are currently 
needed to establish the potential role of IL-6 and IL-8 in supplementing prognosis scoring 
systems in order to achieve a more accurate identification of patients with a greater 
probability of death.  
The most notable finding of this study was the difference in the cytokine profile between 
patients treated with –lactam monotherapy and those treated with combination therapy. 
We found that combination therapy of a –lactam plus fluoroquinolone produced a faster 
decreased in IL-6 in the initial 48 hours of treatment in patients with PP. Taking into 
account the relationship between IL-6 and poor prognosis for PP, the modulation of the 
expression of this cytokine may be a key point for improving patient outcomes. Whether 
combination therapy can improve outcomes in patients with CAP is a controversial issue 
[21-26]. Moreover, most studies have used the combination of –lactam plus macrolide, 
not –lactam plus fluoroquinolone. 
A possible explanation for the differences observed in the pattern of systemic cytokine 
production over time is that -lactam cell wall activity causes the release of cell wall 



































































combination therapy offers more rapid microbial killing due to the presence of quinolones 
and hence shortens the exposure of the host to microbial products. Additionally, 
fluoroquinolones have an intrinsic immunomodulation effect that inhibits the production of 
certain pro-inflammatory cytokines [15-18,31]. The possible beneficial effects of 
fluoroquinolones on the systemic expression of cytokine response when combined with 
-lactam therapy in patients with PP have not been previously explored, but our results 
suggest that their potential anti-inflammatory and immunomodulatory effects persist 
when combined with -lactam. A previous study [8] explored the effects of 
fluoroquinolone monotherapy in modulating the cytokine response in patients with PP, 
finding that it achieved a faster decrease in serum TNF- production at 120 hours post-
admission than -lactam monotherapy.  
Our study has limitations that should be acknowledged. First, the study was 
observational and included a relatively small number of patients. Second, only four 
patients were treated with fluoroquinolone monotherapy, precluding comparisons in the 
pattern of systemic expression of cytokine production. Finally, it should be emphasized 
that our aim was not to establish whether combination therapy of -lactam plus 
fluoroquinolone has a clear impact on survival in the first hours after admission for PP. 
Therefore, our results should be interpreted with caution. 
We found that IL-6, IL-8, IL-10 were detected in venous blood samples in all patients with 
PP at hospital admission with a rapid decrease in the first 48h, correlating with clinical 
defervescence. High levels of IL-6 were found in patients with the worst outcomes. Initial 
-lactam and fluoroquinolone combination antibiotic therapy produced a faster decrease 
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N=52   % 
Demographics 
   Age, mean years (SD) 58.8 (19.3) 
   Male, sex 34 65.4 
   Current smoker 21 40.4 
   Heavy drinking 4 7.7 
Vaccination status 
   Influenza vaccine (season) 11 21.2 
   Pneumococcal vaccination e   4 7.7 
Underlying disease  
   COPDf 14 26.9 
   Chronic heart disease 10 19.2 
   Diabetes mellitus 9 17.3 
   Cerebrovascular disease 4 7.7 
   Chronic liver disease 1 1.9 
   Chronic renal disease 0 0 
Time from pneumonia onset to inclusion 2 (0-15) 
Previous use of statins 6 11.5 
Concomitant use of steroids 2 3.8 
Concomitant use of NSAI* drugs 5 9.6 
High risk PSI (IV-V) 31 59.6 



































































 Altered mental status on admission 11 21.1 
 Renal failure (Cr > 150 mmol/L) 15 28.8 
 Urea median mmol/dl (range) 9.5 (2-30) 
 Heart rate mean (SD) 104.5 (19.20) 
 Respiratory rate mean (SD) 33.5 (9.6) 
 Temperature median (range) 38.5 (36-40) 
 Leucocytes mean (SD) 14431 (7406) 
 PO2/fiO2f mean (SD) 243 (43.8) 
 PO2/fiO2f < 300 43 82.7 
 Multilobar infiltrates 24 46.2 
 Shock at admission 7 13.5 
 Pleural effusion 12 23.1 
 



































































Figure 1. Sequential cytokine levels in patients with severe pneumococcal pneumonia. 
All cytokines except TNF-, showed a statistically significant trend towards a rapid 
decrease after 24  
 



























         

























































































Table 2. Outcomes of pneumococcal pneumonia of patients hospitalized for 
community-acquired pneumonia.   
 
Outcomes All 
n =52         % 
Bacteremia 21 36.8 
ICU admission 15 29 
Length of ICU admission median (range) 5.5 (2- 72) 
Need for mechanical ventilation 9 17.3 
   Non-invasive mechanical ventilation 3 5.7 
   Invasive mechanical ventilation 6 11.5 
Mechanical ventilation-free days median (range) 6.5 (2- 72) 
Early mortality 1 1.9 
Overall mortality 8 15.4 




























































p No (n=37) 
Median (P25-75)  
Yes (n=15) 
Median (P25-75) 







































































































































































































































Table 4. Demographic characteristics, main clinical features and outcomes of 










   Age, median years (range) 63.3 (18.0) 56.5 (17.0) .232 
   Male, sex 14 73.7 12 60 .501 
   Current smoker 6 31.6 9 47.4 .508 
   Heavy drinking 3 15.8 1 5 .287 
Vaccination status 
   Influenza vaccine (season) 4 21.0 5 25.0 .317 
   Pneumococcal vaccination e   1 5.2 3 15.0 .699 
Underlying disease  
   COPDf 7 36.8 4 20.0 .160 
   Chronic heart disease 9 47.4 0 0 <.001 
   Diabetes mellitus 4 21.1 3 15.0 .451 
   Cerebrovascular disease 3 15.8 0 0 .036 
   Chronic liver disease 1 5.3 0 0 .241 
   Chronic renal disease 0 0 0 0 1 
Time from pneumonia onset to inclusion 2.5 (0-15) 3 (1-15) .975 
Previous use of statins 3 15.8 2 10.0 .661 
Concomitant use of steroids  2 10.5 0 0 .230 
Concomitant use of NSAI* drugs 3 15.8 0 0 .106 




































































 Altered mental status on admission 4 21.0 3 15.0 .451 
 Renal failure (Cr > 150 mmol/L) 8 42.1 5 25.0 .320 
 Urea median mmol/dl (range) 11 (2-30) 11 (5-25) .538 
 Respiratory rate mean (SD) 31.9 (8.3)  36.9 (9.1) .123 
Temperature median (range) 38.5 (37.7-38.2) 38.5 (36-40) .813 
 PO2/fiO2f mean (SD) 238.0 (43.0) 232.6 (42.6) .760 
 PO2/fiO2f < 300 16 84.2 18 90 .146 
 Multilobar infiltrates 2 10.5 18 90 <0.001 
 Shock at admission 3 15.8 3 15.0 .408 
 Pleural effusion 3 15.8 5 25.0 .727 
Bacteremia 8 42.1 6 30.0 .325 
Outcomes 
ICU admission 6 31.6 6 30.0 1 
Need for mechanical ventilation 3 15.8 4 20.0 .732 
Early mortality 1 5.3 0 0 .299 
Overall mortality 3 15.8 5 25.0 .694 
 



































































 Figure 2. Evolution of IL-6 and Il-10 systemic concentrations by treatment group. IL-6 
decreased faster in the combination therapy group (p=0.016). Conversely, levels of 
anti-inflammatory cytokines were higher in this group (p <0.001). This analysis has 
been adjusted for potential confounder variables (i.e. the use of corticosteroids or ICU 
admission) 
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